Case number 1:22-cv-02868
Ingenus Pharmaceuticals, LLC et al v. Nexus Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 19, 2024 | 82 | EXECUTIVE COMMITTEE ORDER: Case reassigned to the Honorable Mary M. Rowland for all further proceedings pursuant to Internal Operating Procedure 13(d). Honorable Sunil R. Harjani no longer assigned to the case. Signed by Executive Committee on 4/19/2024. (ph, ) (Entered: 04/19/2024) (1) |
| Apr 2, 2024 | 81 | EXECUTIVE COMMITTEE ORDER: GENERAL ORDER 24-0008: IT APPEARING THAT, the civil cases on the attached list have been selected for reassignment to form the initial calendar of the Honorable Sunil R. Harjani; therefore IT IS HEREBY ORDERED that the attached list of 290 cases be reassigned to the Honorable Sunil R. Harjani; and IT IS FURTHER ORDERED that all parties affected by this Order must review the Honorable Sunil R. Harjani's webpage on the Court's website for the purpose of reviewing instructions regarding scheduling and case management procedures; and IT IS FURTHER ORDERED that any civil case that has been reassigned pursuant to this Order will not be randomly reassigned to create the initial calendar of a new district judge for twelve months from the date of this Order; and IT IS FURTHER ORDERED that the Clerk of Court is directed to add the Honorable Sunil R. Harjani to the Court's civil case assignment system during the next business day, so that he shall receive a full share of such cases; and IT IS FURTHER ORDERED that the Clerk of Court is directed to add the Honorable Sunil R. Harjani to the Court's criminal case assignment system ninety (90) days so that Judge Harjani shall thereafter receive a full share of such cases. Case reassigned to the Honorable Sunil R. Harjani for all further proceedings. Honorable Mary M. Rowland no longer assigned to the case. Signed by Honorable Rebecca R. Pallmeyer on 4/02/2024.(tg, ) (Entered: 04/02/2024) (9) |
| Jan 29, 2024 | 80 | NOTIFICATION of Affiliates pursuant to Local Rule 3.2 by Ingenus Pharmaceuticals, LLC (Griffith, Christopher) (Entered: 01/29/2024) (2) |
| Dec 28, 2023 | 79 | ANNUAL REMINDER: Pursuant to Local Rule 3.2 (Notification of Affiliates), any nongovernmental party, other than an individual or sole proprietorship, must file a statement identifying all its affiliates known to the party after diligent review or, if the party has identified no affiliates, then a statement reflecting that fact must be filed. An affiliate is defined as follows: any entity or individual owning, directly or indirectly (through ownership of one or more other entities), 5% or more of a party. The statement is to be electronically filed as a PDF in conjunction with entering the affiliates in CM/ECF as prompted. As a reminder to counsel, parties must supplement their statements of affiliates within thirty (30) days of any change in the information previously reported. This minute order is being issued to all counsel of record to remind counsel of their obligation to provide updated information as to additional affiliates if such updating is necessary. If counsel has any questions regarding this process, this LINK will provide additional information. Signed by the Executive Committee on 12/28/2023: Mailed notice. (tg, ) (Entered: 12/29/2023) (1) |
| Sep 18, 2023 | 78 | TRANSCRIPT OF PROCEEDINGS held on 8/25/23 before the Honorable Mary M. Rowland. Markman hearing and 12(c) argument. Order Numbers: 46723, 46802. Court Reporter Contact Information: Laura Renke, OfficialTranscript@gmail.com, 312.435.6053. IMPORTANT: The transcript may be viewed at the court's public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through the Court Reporter/Transcriber or PACER. For further information on the redaction process, see the Court's web site at www.ilnd.uscourts.gov under Quick Links select Policy Regarding the Availability of Transcripts of Court Proceedings. Redaction Request due 10/9/2023. Redacted Transcript Deadline set for 10/19/2023. Release of Transcript Restriction set for 12/18/2023. (Renke, Laura) (Entered: 09/18/2023) (131) |
| Aug 25, 2023 | 77 | MINUTE entry before the Honorable Mary M. Rowland: In person claim construction hearing held. The court will rule by mail. Mailed notice. (dm, ) (Entered: 08/25/2023) (1) |
| Aug 24, 2023 | 76 | MINUTE entry before the Honorable Mary M. Rowland: The court has reviewed the status report 73 and accepts the parties' proposal that they conduct a 30-minute tutorial prior to the claim construction hearing. As the hearing, the Defendant will argue the first term "ethanol content of about 70% to about 75%" and then Plaintiffs will respond, and then on to the second and third terms. The court adopts the parties' agreed construction of the term cyclophosphamide. Parties should bring all exhibits on a thumb drive to submit at the close of the hearing. Hearing will be limited to 2 hours, excluding the tutorial. The court's display devices are available to the parties' use. Mailed notice. (dm, ) (Entered: 08/24/2023) (1) |
| Jul 11, 2023 | 75 | MINUTE entry before the Honorable Mary M. Rowland: Telephonic status hearing held. Counsel appeared telephonically. In-person claim construction hearing is re-set for 8/25/23 at 9:00 AM. The court will reserve 3 hours for the hearing and tutorial. Court will also hear argument on the pending motion for partial judgment on pleadings. Mailed notice. (dm, ) (Entered: 07/11/2023) (1) |
| Jul 5, 2023 | 74 | MINUTE entry before the Honorable Mary M. Rowland: Due to travel, the court strikes the in-person claim construction hearing set for 7/20/23. Telephonic status to reset hearing is set for 7/11/23 at 9:30am. Parties should call 866-434-5269; access code 3751971. Mailed notice. (dm, ) (Entered: 07/05/2023) (1) |
| Jun 12, 2023 | 73 | Joint Claim Construction Chart and Status Report by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Attachments: # 1 Exhibit A)(Griffith, Christopher) (Entered: 06/12/2023) (0) |
| Jun 8, 2023 | 72 | MINUTE entry before the Honorable Mary M. Rowland: Defendant's unopposed motion for leave to file under seal 71 is granted. Mailed notice. (dm, ) (Entered: 06/08/2023) (1) |
| Jun 7, 2023 | 71 | MOTION by Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. to seal Foot Note 1 of Nexus's Reply Claim Construction Brief (Attachments: # 1 Nexus Redacted Reply Claim Construction Brief)(Watson, Chad) (Entered: 06/07/2023) (0) |
| Jun 5, 2023 | 70 | Reply Claim Construction Brief by Nexus Pharmaceuticals, Inc. (Watson, Chad) (Entered: 06/05/2023) (0) |
| Jun 5, 2023 | 69 | AMENDED other, 51 Defendant's Amended Opening Claim Construction Brief with Citations to Joint Appendix (Attachments: # 1 Appendix Joint Appendix)(Watson, Chad) (Entered: 06/05/2023) (0) |
| May 31, 2023 | 68 | REPLY by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP to Response, 60 by Defendant to Plaintiffs' Motion for Judgment on the Pleadings 43 (Griffith, Christopher) (Entered: 05/31/2023) (18) |
| May 26, 2023 | 67 | MINUTE entry before the Honorable Mary M. Rowland: Video status hearing held. The court has reviewed the status reports containing the parties' positions about defendants' second Rule 60(b)(6) notice. The court will allow the second Notice. Defendant is not permitted to cover the same topics that have already been covered however. Plaintiffs' Motion for Judgement on the Pleadings remains pending. Mailed notice. (dm, ) (Entered: 05/30/2023) (1) |
| May 22, 2023 | 66 | Plaintiffs' Responsive Claim Construction Brief by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) (Entered: 05/22/2023) (30) |
| May 22, 2023 | 65 | STATUS Report (Joint) by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) (Entered: 05/22/2023) (3) |
| May 22, 2023 | 64 | MINUTE entry before the Honorable Mary M. Rowland: Video status conference set for 5/26/23 at 10:30am to discuss Defendant's second Rule 30(b)(6) notice and 23-2871. Counsel of record will receive an email with a link to join the video conference prior to the hearing. Members of the public and media will be able to call in to listen to this hearing. The call-in number is 650-479-3207 and the call-in ID is 1801732451. Persons granted remote access to proceedings are reminded of the general prohibition against photographing, recording, and rebroadcasting of court proceedings. Violation of these prohibitions may result in sanctions, including removal of court issued media credentials, restricted entry to future hearings, denial of entry to future hearings, or any other sanctions deemed necessary by the Court. Mailed notice. (dm, ) (Entered: 05/22/2023) (1) |
| May 19, 2023 | 63 | MINUTE entry before the Honorable Mary M. Rowland: Joint motion to extend the deadline for the completion of pre-claim construction fact discovery 62 is granted. The deadline for the completion of pre-claim construction fact discovery is extended to June 2, 2023. The proposed two-day extension will not affect any other dates in the current scheduling order. In person claim construction hearing is set for 7/20/23 at 1:00PM. Mailed notice. (dm, ) (Entered: 05/19/2023) (1) |
| May 18, 2023 | 62 | MOTION by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP, Counter Defendants Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP for extension of time to complete discovery (Joint Motion by All Parties) (Griffith, Christopher) (Entered: 05/18/2023) (3) |
| May 12, 2023 | 61 | MINUTE entry before the Honorable Mary M. Rowland: As the parties are aware, the matter of the deposition subpoena for Mr. Iyer was recently transferred to this court in Third Party Subpoenas Ad Testificandum v. Nexus Pharm. Inc, 23-2871. Parties are in agreement that the deposition of Mr. Iyer should be decided following the ruling on the pending motion for judgment on the pleadings and will be litigated in this matter. Parties are to file a joint status report by 5/22/23 indicating whether they agree that court can close case number 23-2871. Mailed notice. (dm, ) (Entered: 05/12/2023) (1) |
| May 9, 2023 | 60 | RESPONSE by Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. to motion for judgment on the pleadings, 43 (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Watson, Chad) (Entered: 05/09/2023) (0) |
| May 2, 2023 | 59 | MINUTE entry before the Honorable Mary M. Rowland: The court has reviewed the joint status report. The matter of Mr. Iyer's deposition is back before this court. It appears the parties agree that matter should be decided following a ruling on pending motion for judgment on the pleadings. Parties should file the raise the matter via motion at the appropriate time. Mailed notice. (dm, ) (Entered: 05/02/2023) (1) |
| Apr 28, 2023 | 58 | Defendant Nexus's Submission re Second 30(b)(6) notice served on Plaintiff Leiutis by Nexus Pharmaceuticals, Inc. (Watson, Chad) (Entered: 04/28/2023) (8) |
| Apr 28, 2023 | 57 | Plaintiffs' Opposition to Defendant's Second Notice of Deposition to Plaintiff Leiutis Pharmaceuticals LLP Under Fed. R. Civ. P. 30(b)(6) by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Griffith, Christopher) (Entered: 04/28/2023) (0) |
| Apr 28, 2023 | 56 | MINUTE entry before the Honorable Mary M. Rowland: Motions to appear pro hac vice by Chidambaram Subramanian Iyer 53 and Lawrence Roman Rachuba II 54 are granted. Counsel are reminded to become familiar with this court's local rules. Mailed notice. (dm, ) (Entered: 04/28/2023) (1) |
| Apr 26, 2023 | 55 | Joint Status Report by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Attachments: # 1 Exhibit A)(Griffith, Christopher) (Entered: 04/26/2023) (0) |
| Apr 26, 2023 | 54 | MOTION for Leave to Appear Pro Hac Vice Filing fee $ 150, receipt number AILNDC-20579723. (Rachuba, Lawrence) (Entered: 04/26/2023) (2) |
| Apr 26, 2023 | 53 | MOTION for Leave to Appear Pro Hac Vice Filing fee $ 150, receipt number AILNDC-20578322. (Iyer, Chidambaram) (Entered: 04/26/2023) (2) |
| Apr 26, 2023 | 52 | MINUTE entry before the Honorable Mary M. Rowland: Motion to appear pro hac vice by John T. Callahan 50 is granted. Counsel is reminded to become familiar with this court's local rules. Mailed notice. (dm, ) (Entered: 04/26/2023) (1) |
| Apr 24, 2023 | 51 | Defendant's Opening Claim Construction Brief by Nexus Pharmaceuticals, Inc. (Attachments: # 1 Exhibit Exhibit A, # 2 Exhibit Exhibit B, # 3 Exhibit Exhibit C, # 4 Exhibit Exhibit D, # 5 Exhibit Exhibit E, # 6 Exhibit Exhibit F, # 7 Exhibit Exhibit G, # 8 Exhibit Exhibit H, # 9 Exhibit Exhibit I, # 10 Exhibit Exhibit J)(Watson, Chad) (Entered: 04/24/2023) (0) |
| Apr 24, 2023 | 50 | MOTION for Leave to Appear Pro Hac Vice Filing fee $ 150, receipt number AILNDC-20569866. (Callahan, John) (Entered: 04/24/2023) (2) |
| Apr 24, 2023 | 49 | MINUTE entry before the Honorable Mary M. Rowland: Motion to appear pro hac vice by Michael Dzwonczyk 48 is granted. Counsel is reminded to become familiar with this court's local rules. Mailed notice. (dm, ) (Entered: 04/24/2023) (1) |
| Apr 22, 2023 | 48 | MOTION for Leave to Appear Pro Hac Vice Filing fee $ 150, receipt number AILNDC-20566850. (Dzwonczyk, Michael) (Entered: 04/22/2023) (2) |
| Apr 20, 2023 | 47 | MINUTE entry before the Honorable Mary M. Rowland: Telephonic status hearing held. Counsel appeared telephonically. For the reasons stated on the record, the deadline for the close of pre-claim construction fact discovery is extended to May 31, 2023. Further deadlines set forth in Dkt. 22 remain unchanged. Parties are working through discovery disputes. Parties are to file position papers, limited to 5 pages, regarding defendant is permitted to serve a second Rule 30(b)(6) notice by 4/28/23. In person claim construction hearing is set for 7/20/23 at 1:00PM. Mailed notice. (dm, ) (Entered: 04/20/2023) (1) |
| Apr 19, 2023 | 46 | Joint Status Report by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) (Entered: 04/19/2023) (4) |
| Apr 19, 2023 | 45 | MOTION by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP, Counter Defendants Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP for extension of time to complete discovery (Griffith, Christopher) (Entered: 04/19/2023) (4) |
| Apr 11, 2023 | 44 | MINUTE entry before the Honorable Mary M. Rowland: Defendant's response to Plaintiffs' motion for judgment on the pleadings 43 is due 5/9/23. Plaintiffs' reply is due 5/31/23. Telephonic status hearing remains set for 4/20/23 at 9:30 a.m. 33 Mailed notice. (dm, ) (Entered: 04/11/2023) (1) |
| Apr 10, 2023 | 43 | MOTION by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP, Counter Defendants Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP for judgment on the pleadings pursuant to Fed. R. Civ. P. 12(c) (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M)(Griffith, Christopher) (Entered: 04/10/2023) (0) |
| Mar 24, 2023 | 42 | Plaintiffs ANSWER to counterclaim s (First Amended) by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S, # 20 Exhibit T, # 21 Exhibit U, # 22 Exhibit V, # 23 Exhibit W)(Griffith, Christopher) (Entered: 03/24/2023) (0) |
| Feb 22, 2023 | 41 | AMENDED answer to complaint, counterclaim 15 Nexus's First Amended Counterclaims (Attachments: # 1 Exhibit Exhibit A, # 2 Exhibit Exhibit B, # 3 Exhibit Exhibit C, # 4 Exhibit Exhibit D, # 5 Exhibit Exhibit E, # 6 Exhibit Exhibit F, # 7 Exhibit Exhibit G)(Watson, Chad) (Entered: 02/22/2023) (0) |
| Feb 22, 2023 | 40 | MINUTE entry before the Honorable Mary M. Rowland: Defendant's motion for leave to amend counterclaims 39 is granted. Defendant shall file first amended counterclaims as a separate entry on the docket by 2/24/23. Responsive pleading due 3/24/23. Mailed notice. (dm, ) (Entered: 02/22/2023) (1) |
| Feb 21, 2023 | 39 | MOTION by Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. for leave to file Nexus's First Amended Counterclaims (Attachments: # 1 Exhibit Nexus's First Amended Counterclaims with Exhibits)(Watson, Chad) (Entered: 02/21/2023) (0) |
| Feb 8, 2023 | 38 | MINUTE entry before the Honorable Mary M. Rowland: Defendant's motion to compel the deposition testimony of Chidambaram Iyer 32 is denied without prejudice. The proper forum for a motion to compel compliance with a subpoena, or for a motion to quash a subpoena, is the district court where compliance with the subpoena is required. See Fed. R. Civ. P. 45(d)(2)(A)(i) ("At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection."), (d)(3) (providing certain conditions under which "the court for the district where compliance is required must quash or modify a subpoena"). Here, compliance is required in the District of Columbia, the place where Mr. Iyer works and lives. See Fed. R. Civ. P. 45(c)(1)(A); [36-2] at 2. The district court in the District of Columbia must therefore decide whether Mr. Iyer must submit to the deposition, or alternatively, exercise its discretion to transfer the dispute to this Court. See Fed. R. Civ. P. 45(f) ("When the court where compliance is required did not issue the subpoena, it may transfer a motion under this rule... if the court finds exceptional circumstances."). This Court must allow that process to play out, and for that reason, denies Defendant's motion to compel without prejudice. In light of the above, this Court denies Plaintiff's motion to stay briefing 36 as moot and strikes the 2/14/23 motion hearing. The parties shall file a status report within 3 business days of a ruling by the District of Columbia district court on the motion to quash. Telephonic status hearing remains set for 4/20/23 at 9:30 a.m. Mailed notice. (dm, ) (Entered: 02/08/2023) (2) |
| Feb 7, 2023 | 37 | MINUTE entry before the Honorable Mary M. Rowland: Defendant's unopposed motion for leave to file under seal 35 is granted. Mailed notice. (dm, ) (Entered: 02/07/2023) (1) |
| Feb 6, 2023 | 36 | MOTION by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP, Counter Defendants Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP to stay Briefing on and Consideration of Defendant's Motion to Compel the Deposition Testimony of Chidambaram Iyer (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Griffith, Christopher) (Entered: 02/06/2023) (0) |
| Feb 6, 2023 | 35 | MOTION by Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. to seal document MOTION by Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. to compel Deposition Testimony of Chidambaram Iyer 32 (Watson, Chad) (Entered: 02/06/2023) (3) |
| Feb 6, 2023 | 34 | MINUTE entry before the Honorable Mary M. Rowland: Hearing on Defendant's motion to compel 32 is set for 2/14/23 at 9:45 am. Parties should call 866-434-5269; access code 3751971. Mailed notice. (dm, ) (Entered: 02/06/2023) (1) |
| Feb 6, 2023 | 33 | MINUTE entry before the Honorable Mary M. Rowland: The court has reviewed the joint status report. Discovery is on track as set forth in the scheduling order. Claim construction fact discovery is set to close on 4/24/23. 22 Telephonic status set for 4/20/23 at 9:30am. Parties should call 866-434-5269; access code 3751971. Mailed notice. (dm, ) (Entered: 02/06/2023) (1) |
| Feb 3, 2023 | 32 | MOTION by Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. to compel Deposition Testimony of Chidambaram Iyer (Attachments: # 1 Text of Proposed Order Proposed Order, # 2 Exhibit Exhibit A, # 3 Exhibit Exhibit B, # 4 Exhibit Exhibit C, # 5 Exhibit Exhibit D, # 6 Exhibit Exhibit E, # 7 Exhibit Exhibit F, # 8 Exhibit Exhibit G, # 9 Exhibit Exhibit H, # 10 Exhibit Exhibit I, # 11 Exhibit Exhibit J)(Watson, Chad) (Entered: 02/03/2023) (0) |
| Jan 31, 2023 | 31 | JOINT STATUS REPORT by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Attachments: # 1 Exhibit Exhibit A)(Griffith, Christopher) (Entered: 01/31/2023) (0) |
| Jan 18, 2023 | 30 | ATTORNEY Appearance for Defendant Nexus Pharmaceuticals, Inc. by Chad Forrest Watson (Watson, Chad) (Entered: 01/18/2023) (1) |
| Dec 29, 2022 | 29 | ANNUAL REMINDER: Pursuant to Local Rule 3.2 (Notification of Affiliates), any nongovernmental party, other than an individual or sole proprietorship, must file a statement identifying all its affiliates known to the party after diligent review or, if the party has identified no affiliates, then a statement reflecting that fact must be filed. An affiliate is defined as follows: any entity or individual owning, directly or indirectly (through ownership of one or more other entities), 5% or more of a party. The statement is to be electronically filed as a PDF in conjunction with entering the affiliates in CM/ECF as prompted. As a reminder to counsel, parties must supplement their statements of affiliates within thirty (30) days of any change in the information previously reported. This minute order is being issued to all counsel of record to remind counsel of their obligation to provide updated information as to additional affiliates if such updating is necessary. If counsel has any questions regarding this process, this LINK will provide additional information. Signed by the Executive Committee on 12/29/2022: Mailed notice. (tg, ) (Entered: 12/29/2022) (1) |
| Nov 21, 2022 | 28 | MINUTE entry before the Honorable Mary M. Rowland: The Court has reviewed the parties' status report. Parties indicate they have resolved some preliminary discovery matters. Parties are to file un updated status report by 1/31/23. The Court strikes the status hearing set for 11/21/22 at 9:30 AM. Mailed notice. (dm, ) (Entered: 11/21/2022) (1) |
| Nov 18, 2022 | 27 | Joint Status Report by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) (Entered: 11/18/2022) (2) |
| Oct 12, 2022 | 26 | MINUTE entry before the Honorable Mary M. Rowland: Plaintiff's motion to extend the deadline to serve their initial response to non-infringement and invalidity contentions 23 is granted. The new date for said response is 10/28/22. This date will not be extended again. The Court strikes the status report due 10/31/22 22 and sets a telephonic status for 11/21/22 at 9:30 AM. Parties should call 866-434-5269; access code 3751971. Persons granted remote access to proceedings are reminded of the general prohibition against photographing, recording, and rebroadcasting of court proceedings. Violation of these prohibitions may result in sanctions, including removal of court issued media credentials, restricted entry to future hearings, denial of entry to future hearings, or any other sanctions deemed necessary by the Court. Mailed notice. (dm, ) (Entered: 10/12/2022) (1) |
| Oct 11, 2022 | 25 | REPLY by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP, Counter Defendants Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP in Support of Their Motion to Extend the Deadline for Service of Their Initial Response to Noninfringement and Invalidity Contentions (Griffith, Christopher) (Entered: 10/11/2022) (4) |
| Oct 11, 2022 | 24 | RESPONSE by Nexus Pharmaceuticals, Inc.in Opposition to MOTION by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP, Counter Defendants Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP for extension of time to serve their initial response to Defendant's initial non-infring 23 (Wallace, Joel) (Entered: 10/11/2022) (6) |
| Oct 10, 2022 | 23 | MOTION by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP, Counter Defendants Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP for extension of time to serve their initial response to Defendant's initial non-infringement and invalidity contentions (Griffith, Christopher) (Entered: 10/10/2022) (5) |
| Aug 31, 2022 | 22 | ORDER Signed by the Honorable Mary M. Rowland on 8/31/2022. On or before 10/31/22, the parties shall file a joint status report updating the court on the status of discovery and whether a settlement conference would be productive. Mailed notice. (dm, ) (Entered: 08/31/2022) (4) |
| Aug 29, 2022 | 21 | REPORT of Rule 26(f) Planning Meeting by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) (Entered: 08/29/2022) (13) |
| Aug 15, 2022 | 20 | ANSWER to counterclaim by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP(Griffith, Christopher) (Entered: 08/15/2022) (9) |
| Jul 28, 2022 | 18 | attorney appearance (1) Docket Text: ATTORNEY Appearance for Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. by Sailesh K. Patel (Patel, Sailesh) |
| Jul 28, 2022 | 19 | attorney appearance (1) Docket Text: ATTORNEY Appearance for Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. by Imron T Aly (Aly, Imron) |
| Jul 25, 2022 | 17 | attorney appearance (1) Docket Text: ATTORNEY Appearance for Counter Claimant Nexus Pharmaceuticals, Inc., Defendant Nexus Pharmaceuticals, Inc. by Joel M Wallace (Wallace, Joel) |
| Jul 25, 2022 | 16 | notification of affiliates pursuant to local rule 3.2 (2) Docket Text: NOTIFICATION of Affiliates pursuant to Local Rule 3.2 by Nexus Pharmaceuticals, Inc. (Wallace, Joel) |
| Jul 25, 2022 | 15 | answer to complaint (24) Docket Text: ANSWER to Complaint , Affirmative Defenses, and COUNTERCLAIM filed by Nexus Pharmaceuticals, Inc. against Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP . by Nexus Pharmaceuticals, Inc.(Wallace, Joel) |
| Jun 23, 2022 | 14 | order on motion for miscellaneous relief (1) Docket Text: MINUTE entry before the Honorable Mary M. Rowland: Plaintiff's motion to amend proof of service [12] is granted. The proof of service filed on June 9, 2022 and answer date of June 27, 2022 are vacated. Waiver of Service was returned executed on 6/22/22. Answer is due 8/15/22. The deadline of 8/3/22 for parties to file a report of the parties' planning meeting [8] is reset to 8/29/22. Mailed notice. (dm, ) |
| Jun 23, 2022 | 13 | order on motion to appear pro hac vice (1) Docket Text: MINUTE entry before the Honorable Mary M. Rowland: Motion to appear pro hac vice by Michael Dzwonczyk [11] is granted. Counsel is reminded to become familiar with this court's local rules (including the rules requiring local counsel and describing this court's trial bar). Mailed notice. (dm, ) |
| Jun 22, 2022 | 12 | motion for miscellaneous relief (3) Docket Text: MOTION by Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLPMotion to Amend Proof of Service Pursuant to Fed. R. Civ. P. 4(l)(3) (Griffith, Christopher) |
| Jun 22, 2022 | 11 | motion to appear pro hac vice (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice Filing fee $ 150, receipt number AILNDC-19584542. Michael R. Dzwonczyk (Griffith, Christopher) |
| Jun 22, 2022 | 10 | waiver of service executed (1) Docket Text: WAIVER OF SERVICE returned executed by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP. Nexus Pharmaceuticals, Inc. waiver sent on 6/15/2022, answer due 8/15/2022. (Griffith, Christopher) |
| Jun 9, 2022 | 9 | summons returned executed (1) Docket Text: SUMMONS Returned Executed by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP as to Nexus Pharmaceuticals, Inc. on 6/6/2022, answer due 6/27/2022. (Griffith, Christopher) |
| Jun 7, 2022 | 8 | set deadlines (1) Docket Text: MINUTE entry before the Honorable Mary M. Rowland: On or before 8/3/22, the parties shall file a report of the parties' planning meeting pursuant to LPR 1.2. A template for the report setting forth the information required may be found in Judge Rowland's standing order on Patent Cases, available on her webpage, by clicking the link in the Patent Cases standing order, "LPR Appendix A." Parties shall also report on the status of any settlement discussions. Mailed notice. (dm, ) |
| Jun 3, 2022 | 7 | (List of Patents) (5) |
| Jun 3, 2022 | 7 | Main Document (1) Docket Text: MAILED Patent report to Patent Trademark Office, Alexandria VA (Attachments: # (1) (List of Patents))(ph, ) |
| Jun 3, 2022 | N/A | summons issued (0) Docket Text: SUMMONS Issued as to Defendant Nexus Pharmaceuticals, Inc. (khg, ) |
| Jun 1, 2022 | 1 | Complaint* (1) |
| Jun 1, 2022 | 6 | other (3) Docket Text: Notice of Claims Involving Patents Under Local Rule 3.4 by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP (Griffith, Christopher) |
| Jun 1, 2022 | 5 | notification of affiliates pursuant to local rule 3.2 (2) Docket Text: NOTIFICATION of Affiliates pursuant to Local Rule 3.2 by Leiutis Pharmaceuticals LLP (Griffith, Christopher) |
| Jun 1, 2022 | 4 | notification of affiliates pursuant to local rule 3.2 (2) Docket Text: NOTIFICATION of Affiliates pursuant to Local Rule 3.2 by Ingenus Pharmaceuticals, LLC (Griffith, Christopher) |
| Jun 1, 2022 | 3 | attorney appearance (1) Docket Text: ATTORNEY Appearance for Plaintiffs Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP by Christopher Thomas Griffith (Griffith, Christopher) |
| Jun 1, 2022 | 2 | civil cover sheet (1) Docket Text: CIVIL Cover Sheet (Griffith, Christopher) |
| Jun 1, 2022 | 1 | Exhibit Exh A. - US Patent 10,993,952 (5) |
| Jun 1, 2022 | 1 | Main Document (11) Docket Text: COMPLAINT filed by Ingenus Pharmaceuticals, LLC, Leiutis Pharmaceuticals LLP; Filing fee $ 402, receipt number AILNDC-19518503. (Attachments: # (1) Exhibit Exh A. - US Patent 10,993,952)(Griffith, Christopher) |
| Jun 1, 2022 | N/A | clerk's notice (0) Docket Text: CLERK'S NOTICE: Pursuant to Local Rule 73.1(b), a United States Magistrate Judge of this court is available to conduct all proceedings in this civil action. If all parties consent to have the currently assigned United States Magistrate Judge conduct all proceedings in this case, including trial, the entry of final judgment, and all post-trial proceedings, all parties must sign their names on the attached Consent To form. This consent form is eligible for filing only if executed by all parties. The parties can also express their consent to jurisdiction by a magistrate judge in any joint filing, including the Joint Initial Status Report or proposed Case Management Order. (khg, ) |
| Jun 1, 2022 | N/A | case assigned (0) Docket Text: CASE ASSIGNED to the Honorable Mary M. Rowland. Designated as Magistrate Judge the Honorable Maria Valdez. Case assignment: Random assignment. (khg, ) |
